sanofi Archives - Vista Partners LLC | HomeVista Partners LLC

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

by John F. Heerdink, Jr. June 26, 2026 309Views 0Likes

Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. June 19, 2026 366Views 0Likes

Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 389Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. May 6, 2026 389Views 0Likes

Eupraxia’s (NASDAQ: EPRX) latest data drop puts eosinophilic esophagitis (EoE) firmly at center stage, with fresh endoscopic and long‑term clinical results suggesting EP‑104GI could emerge as a once‑yearly, procedure‑based alternative to chronic biologic regimens such as Sanofi’s (SNY) multi-billion dollar weekly-injectable drug…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 532Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 529Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. February 9, 2026 485Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) may still wear the “clinical-stage” name tag, but its stock has been behaving like it already found a seat at the grown‑ups’ table on Wall Street. Over the past year, shares have climbed roughly 160%, far outpacing the…

Tag: sanofi

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY )

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

Your Guide To Staying Informed In The Markets